Definitive Healthcare (NASDAQ:DH) Downgraded to Equal Weight at Morgan Stanley

Morgan Stanley cut shares of Definitive Healthcare (NASDAQ:DH) from an overweight rating to an equal weight rating in a research note published on Wednesday morning, Marketbeat.com reports. They currently have $9.00 target price on the stock, down from their prior target price of $11.50.

DH has been the subject of a number of other research reports. Needham & Company LLC cut Definitive Healthcare from a buy rating to a hold rating in a research report on Wednesday, January 17th. Canaccord Genuity Group lifted their price target on shares of Definitive Healthcare from $9.00 to $10.00 and gave the company a hold rating in a research report on Thursday, February 29th. Stifel Nicolaus lowered their target price on shares of Definitive Healthcare from $12.00 to $11.00 and set a buy rating on the stock in a research note on Wednesday, January 17th. Finally, Barclays boosted their price objective on Definitive Healthcare from $10.00 to $11.00 and gave the stock an equal weight rating in a research report on Friday, March 1st. Eight equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, Definitive Healthcare has an average rating of Hold and an average price target of $10.81.

Definitive Healthcare Stock Down 26.2 %

NASDAQ:DH opened at $5.35 on Wednesday. Definitive Healthcare has a 1-year low of $4.38 and a 1-year high of $12.45. The firm has a market capitalization of $630.18 million, a price-to-earnings ratio of -3.01, a PEG ratio of 6.12 and a beta of 1.41. The company has a current ratio of 2.31, a quick ratio of 2.31 and a debt-to-equity ratio of 0.20. The business’s fifty day moving average price is $7.70 and its 200 day moving average price is $8.29.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.02). Definitive Healthcare had a negative net margin of 80.40% and a positive return on equity of 0.43%. The company had revenue of $65.93 million during the quarter, compared to analyst estimates of $66.01 million. On average, sell-side analysts forecast that Definitive Healthcare will post 0.11 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Definitive Healthcare

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC raised its position in shares of Definitive Healthcare by 599.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,786 shares of the company’s stock worth $58,000 after acquiring an additional 4,959 shares during the last quarter. Norden Group LLC acquired a new position in Definitive Healthcare during the 1st quarter valued at about $83,000. Berry Wealth Group LP bought a new position in shares of Definitive Healthcare in the 1st quarter valued at about $99,000. Reynders McVeigh Capital Management LLC acquired a new stake in shares of Definitive Healthcare during the 4th quarter worth approximately $129,000. Finally, Arizona State Retirement System raised its stake in shares of Definitive Healthcare by 13.6% during the fourth quarter. Arizona State Retirement System now owns 14,253 shares of the company’s stock worth $142,000 after buying an additional 1,701 shares during the last quarter. Institutional investors and hedge funds own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.